Diabetes Mellitus (Type 2) is a major health issue all over the world. It is rapidly growing metabolic disorder characterized by hyperglycaemia with disturbances in carbohydrate, fat and protein metabolism. According to the International Diabetes Federation, more than 380 million people in the world suffer from Diabetes and this number will rise beyond 592 million in less than 25 years. The main classes of anti-diabetic drugs (biguanides, sulphonylureas, a-glucosidase inhibitors, thiazolidinediones, meglitinides) have side effects like weight gain and hypoglycaemia which makes them unsuitable for long term use. Thus newer anti-diabetic agents are still in need. Dipeptidyl Peptidase IV inhibitors have been found to be effective in the treatment of Type 2 Diabetes. DPP IV plays a major role in glucose metabolism. It is responsible for inactivation of incretins like GLP-1. Dipeptidyl Peptidase IV inhibitors increase insulin secretion by enhancing the level of incretin hormones. These incretin hormones are responsible for maintaining postprandial blood glucose levels by stimulating insulin secretion.
Cite this article:
Kavita Chandramore. Review on Dipeptidyl Peptidase IV Inhibitors as a Newer Target for Diabetes Mellitus Treatment. Asian J. Pharm. Res. 2017; 7(4): 230-238. doi: 10.5958/2231-5691.2017.00036.3